A Phase 2 interventional study of Ivacaftor and Placebo-matched-to-ivacaftor tablet in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-05-19.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 65th largest by enrollment, is one of 4 that started in 2012, is one of 17 in phase 2, and was the 18th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 4 started in 2012.
This study's enrollment of 24 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 55 (51%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 95th largest by enrollment of the 116 interventional ones that give a count, is one of 4 that started in 2012, is one of 21 in phase 2, and was the 20th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study is a multiple within participant crossover study to evaluate the effect of ivacaftor on lung function in participants aged 12 years and older with cystic fibrosis (CF) who have phenotypic or molecular evidence of residual CF transmembrane conductance regulator (CFTR) function.
CFTR Mutations associated with residual function or defective messenger ribonucleic acid (mRNA) splicing include the following:
R117H, E56K, P67L, D110E, D110H, R117C, R347H, R352Q, A455E, D579G, S945L, L206W, R1070W, F1074L, D1152H, S1235R, D1270N, 2789+5G->A, 3849+10kbC->T, 3272-26A->G, 711+5G->A, 3120G->A, 1811+1.6kbA->G, 711+3A->G, 1898+3A->G, 1898+1G->A, 1717-1G->A, 1717-8G->A, 1342-2A->C, 405+3A->C, 1716G/A 1811+1G->C, 1898+5G->T, 3850-3T->G, IVS14b+5G->A, 1898+1G->T, 4005+2T->C, 621+3A->G, 621+1G->T.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet
During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet
During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet
During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and Cycle 2 \[(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)\] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
Drug: Ivacaftor · Drug: Placebo-matched-to-ivacaftor tablet
150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
Also known as: Kalydeco, VX-770
Orally every 12 hours up to 4 weeks.
Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)
Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Lung Clearance Index (LCI) After 2 Weeks of Treatment
LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Cycle 1 baseline, Cycle 1 Day 15 (for Cycle 1 reporting arms); Cycle 2 baseline, Cycle 2 Day 15 (for Cycle 2 reporting arms)
Open-label Period: Absolute Change From Open-label Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) at Day 57
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Open-label Baseline, Open-label Day 57
Open-label Period: Absolute Change From Open-label Baseline In Lung Clearance Index (LCI) at Day 57
LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Open-label Baseline, Open-label Day 57
Open-label Period: Absolute Change From Study Baseline In Sweat Chloride at Day 57
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Study Baseline, Open-label Day 57
Open-label Period: Absolute Change From Open-label Baseline In Weight at Day 57
Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
Time frame: Open-label Baseline, Open-label Day 57
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Adverse events (AEs) that started (or increased in severity) from first dose of study drug through completion of Follow-up were considered TEAEs, with exception that if an AE started during a Washout Period and was beyond 14 days from last dose date of preceding cycle, AE was considered as a "Washout Period" AE, and hence not TEAE. A TEAE was attributed to treatment in which it started or to the treatment in second cycling period of previous Crossover Period if it started during a Washout Period. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Data was to be reported by drug treatment for double-blind crossover period (Cycle 1 up to Washout Period 2) and open-label period.
Time frame: From first dose of study drug through completion of follow-up visit (up to 26 weeks)
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 6 | 7 | 6 |
| Completed | 5 | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 6 | 7 | 6 |
| Completed | 5 | 6 | 7 | 5 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 6 | 7 | 5 |
| Completed | 5 | 6 | 7 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 6 | 7 | 5 |
| Completed | 5 | 6 | 7 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 6 | 7 | 5 |
| Completed | 5 | 5 | 7 | 4 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 | 1 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 5 | 7 | 4 |
| Completed | 5 | 5 | 7 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP) | Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI) | Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP) | Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI) |
|---|---|---|---|---|
| Started | 5 | 5 | 7 | 4 |
| Completed | 5 | 5 | 7 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| Percent predicted of FEV1 | Cycle 1: Placebo | Cycle 1: Ivacaftor | Cycle 2: Placebo | Cycle 2: Ivacaftor |
|---|---|---|---|---|
| Overall (n=24, 24, 23, 23) | 0.5828 ± 3.67326 | 2.0898 ± 4.63833 | 0.8495 ± 4.20641 | 3.6868 ± 6.13466 |
| mRNA Splice Site(ClassV)Mutations (n=10, 10, 9, 9) | -0.5710 ± 3.39739 | 0.8196 ± 5.09161 | 1.7132 ± 3.80933 | 2.0640 ± 3.55493 |
| Residual Function Mutations (n=14, 14, 14, 14) | 1.4069 ± 3.75842 | 2.9971 ± 4.24124 | 0.2942 ± 4.49056 | 4.7300 ± 7.27436 |
LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment. Data was to be reported for each cycle (Cycle 1 and Cycle 2) and as per drug treatment, for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| ratio | Cycle 1: Placebo | Cycle 1: Ivacaftor | Cycle 2: Placebo | Cycle 2: Ivacaftor |
|---|---|---|---|---|
| Overall (n=23, 24, 23, 22) | 0.4596 ± 1.97774 | 0.2822 ± 3.54741 | 0.4111 ± 2.39920 | 0.0770 ± 1.98188 |
| mRNA Splice Site(ClassV)Mutations (n=10, 10, 9, 9) | 0.4321 ± 1.97140 | -0.5306 ± 1.91374 | 1.0568 ± 2.12093 | -0.3136 ± 1.89562 |
| Residual Function Mutations (n=13, 14, 14, 13) | 0.4808 ± 2.06279 | 0.8628 ± 4.34252 | -0.0039 ± 2.54929 | 0.3475 ± 2.06990 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| Percent predicted of FEV1 | Open-Label Period: Ivacaftor |
|---|---|
| Overall (n=21) | 4.6815 ± 4.17934 |
| mRNA Splice Site(ClassV)Mutations (n=9) | 4.3072 ± 2.93624 |
| Residual Function Mutations (n=12) | 4.9622 ± 5.02864 |
LCI is a measure of ventilation inhomogeneity that is derived from a multiple-breath washout test. The LCI was calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity \[FRC\]) required to reduce end-tidal concentration of an inert gas to 1/40th of the starting value. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| ratio | Open-label Period: Ivacaftor |
|---|---|
| Overall (n=21) | -1.5687 ± 2.27137 |
| mRNA Splice Site(ClassV)Mutations (n=9) | -1.3459 ± 2.88447 |
| Residual Function Mutations (n=12) | -1.7358 ± 1.80502 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| millimole per liter (mmol/L) | Open-label Period: Ivacaftor |
|---|---|
| Overall (n=19) | -15.74 ± 14.781 |
| mRNA Splice Site(ClassV)Mutations (n=8) | -14.13 ± 8.254 |
| Residual Function Mutations (n=11) | -16.91 ± 18.493 |
Data was to be reported for overall participants and as per genotype (residual function mutation and mRNA splice site mutation).
| kilograms (kg) | Open-label Period: Ivacaftor |
|---|---|
| Overall (n=21) | 1.77 ± 1.906 |
| mRNA Splice Site(ClassV)Mutations (n=9) | 2.32 ± 2.111 |
| Residual Function Mutations (n=12) | 1.35 ± 1.710 |
Adverse events (AEs) that started (or increased in severity) from first dose of study drug through completion of Follow-up were considered TEAEs, with exception that if an AE started during a Washout Period and was beyond 14 days from last dose date of preceding cycle, AE was considered as a "Washout Period" AE, and hence not TEAE. A TEAE was attributed to treatment in which it started or to the treatment in second cycling period of previous Crossover Period if it started during a Washout Period. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Data was to be reported by drug treatment for double-blind crossover period (Cycle 1 up to Washout Period 2) and open-label period.
| participants | Crossover Double-blind Period: Placebo | Crossover Double-blind Period: Ivacaftor | Open-label Period: Ivacaftor |
|---|---|---|---|
| AEs | 17 | 18 | 20 |
| SAEs | 0 | 1 | 0 |
Collected over From first dose of study drug through completion of follow-up visit (up to 26 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Crossover Double-blind Period: Placebo | — | 0/24 (0%) | 17/24 (70.8%) |
| Crossover Double-blind Period: Ivacaftor | — | 1/24 (4.2%) | 18/24 (75%) |
| Open-label Period: Ivacaftor | — | 0/21 (0%) | 20/21 (95.2%) |
| Event | Crossover Double-blind Period: Placebo | Crossover Double-blind Period: Ivacaftor | Open-label Period: Ivacaftor |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/24 | 1/24 | 0/21 |
| Event | Crossover Double-blind Period: Placebo | Crossover Double-blind Period: Ivacaftor | Open-label Period: Ivacaftor |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 6/24 | 1/24 | 7/21 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 7/24 | 1/24 | 2/21 |
| Upper respiratory tract infectionInfections and infestations | 0/24 | 5/24 | 4/21 |
| FatigueGeneral disorders | 3/24 | 0/24 | 4/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/24 | 0/24 | 1/21 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/24 | 1/24 | 2/21 |
| Oral candidiasisInfections and infestations | 3/24 | 0/24 | 0/21 |
| PyrexiaGeneral disorders | 1/24 | 3/24 | 0/21 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/24 | 1/24 | 2/21 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/24 | 1/24 | 2/21 |
Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug (ivacaftor or placebo).
| Age, Continuous(years) | IPIP | IPPI | PIIP | PIPI | Total |
|---|---|---|---|---|---|
| Mean | 44.8 ± 8.04 | 29.7 ± 11.66 | 41.4 ± 13.96 | 33.8 ± 17.26 | 37.3 ± 13.86 |
| Age, Customized(participants) | IPIP | IPPI | PIIP | PIPI | Total |
|---|---|---|---|---|---|
| less than (<) 20 years | 0 | 1 | 0 | 2 | 3 |
| 20 - 40 years | 1 | 4 | 3 | 2 | 10 |
| greater than (>) 40 years | 4 | 1 | 4 | 2 | 11 |
| Sex: Female, Male(Participants) | IPIP | IPPI | PIIP | PIPI | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 3 | 2 | 12 |
| Male | 2 | 2 | 4 | 4 | 12 |
| Genotype(participants) | IPIP | IPPI | PIIP | PIPI | Total |
|---|---|---|---|---|---|
| mRNA Splice Site (Class V) Mutations | 3 | 3 | 2 | 2 | 10 |
| Residual Function Mutations | 2 | 3 | 5 | 4 | 14 |
The record gives a start of Sep 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →